

# SI Worksheet

OMB #: 0925-0753

Expiration Date: 07/31/2021

[Add Note](#)

## STATEMENT OF CONFIDENTIALITY

The purpose of the information collection is to conduct reviews of clinical trial studies. NCI guidelines mandate the participation of institutions in the CIRB for Network group studies. You are being requested to complete this instrument so that we can conduct activities involved with the operations of the NCI CIRB Initiative. Although your participation in Network group research and completion of the forms is voluntary, if you wish to participate in the CIRB, you must complete all questions on the form. The information you provide will be combined for all participants and reported as summaries. It will be kept private to the extent provided by law.

## NOTIFICATION TO RESPONDENT OF ESTIMATED BURDEN

Public reporting burden for this collection of information is estimated to average 40 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0753). Do not return the completed form to this address.

Please refer to the Quickguide on [Completing The Annual Signatory Institution Worksheet](#) for further guidance.

[Add Note](#)

### Reason for submission:

[Add Note](#) [View Audit](#)

(Required)

- First submission to the CIRB of an Annual Signatory Institution Worksheet About Local Context
- Revised submission of the Annual Signatory Institution Worksheet About Local Context

## Signatory Institution Information

[Add Note](#) [View Audit](#)

### Submitting User Information

Campbell, Brian

Email: [bcampbell@emmes.com](mailto:bcampbell@emmes.com)

### Name of Signatory Institution

[Add Note](#) [View Audit](#)

CIRB Operations Office ▾

### Site Reviewer

[Add Note](#) [View Audit](#)

No answer provided.

If there are any changes to the Submitting User Information, please update within the user's Identity and Access Management (IAM) account.

[Add Note](#)

### 1. What type of studies does this Signatory Institution intend to open with the CIRB?

[Add Note](#) [View Audit](#)

(Required)

- Phase 2/3 and Large Phase 2 Adult Studies
- ETCTN and Group Phase 1 and 2 Adult Studies
- Cancer Prevention and Control Studies
- Pediatric Studies

### 2. Verify the list of Component Institutions

[Add Note](#) [View Audit](#)

- The EMMES Corporation

If there are any changes to the list of Component Institutions, update your roster in Roster Update Management System (RUMS).

### 3. Verify the list of Affiliate Institutions

[Add Note](#) [View Audit](#)

If there are any changes to the list of Affiliate Institutions, update your roster in the Roster Update Management System (RUMS).

**State and Local Law**

[Add Note](#) [View Audit](#)

**4. What is your state law and corresponding institutional policy regarding legally authorized representatives?**

(Required)

If applicable, an attachment can be added here.

[Add Note](#) [View Audit](#)

[Add Attachment](#)

**5. What are the other state or local laws that govern the conduct of research at your institution?**

[Add Note](#) [View Audit](#)

(Required)

If applicable, an attachment can be added here.

[Add Note](#) [View Audit](#)

[Add Attachment](#)

**6. What is the age of majority in your state?**

[Add Note](#) [View Audit](#)

(Required)

**Research Oversight**

[Add Note](#) [View Audit](#)

**7. Do you have an IRB that operates at your Signatory Institution?**

(Required)

- Yes
- No

If Yes, identify the office, the person, and the person's title at your institution to whom the IRB reports.

[Add Note](#) [View Audit](#)

**Office Name**

**Responsible Person**

[Add Note](#) [View Audit](#)

**Phone**

[Add Note](#) [View Audit](#)

Email Address [Add Note](#) [View Audit](#)

[Add Note](#)

**8. Identify the office, the person, and the person's title at your institution responsible for the oversight of the conduct of research for studies open under the CIRB. (This person cannot be a Principal Investigator who will open studies with the CIRB or someone who enrolls or interacts with study participants at study visits.)**

Please refer to the [Oversight Q&A](#) Quickguide for further guidance.

Office Name [Add Note](#) [View Audit](#)

Responsible Person [Add Note](#) [View Audit](#)

Phone Number [Add Note](#) [View Audit](#)

Email address [Add Note](#) [View Audit](#)

[Add Note](#)

**Describe, in detail, how this person(s) ensures the safe and appropriate performance of the research at the Signatory Institution and at all Component and Affiliate Institutions, including:**

*NOTE: SOPs, organizational charts, and other documents to support the oversight structure should be attached after item 8(e).*

**a) Ensuring the initial and ongoing qualifications of investigators and research staff.** [Add Note](#) [View Audit](#)

*(Required)*

**b) Overseeing the conduct of the research, including how the person identified fulfills this responsibility.** [Add Note](#) [View Audit](#)

*(Required)*

[Add Note](#) [View Audit](#)

**c) Monitoring protocol compliance, including how the person identified fulfills this responsibility.**

(Required)

[Add Note](#) [View Audit](#)

**d) Maintaining compliance with state, local, or institutional requirements related to the protection of human subjects.**

(Required)

[Add Note](#) [View Audit](#)

**e) Providing a mechanism to receive and address concerns from local study participants and others about the conduct of the research.**

(Required)

[Add Note](#) [View Audit](#)

**If applicable, an attachment(s) can be added here for questions a through e.**

[Add Attachment](#)

[Add Note](#)

**9. Identify the office, the person, and the person's title at your institution responsible for identifying, managing, and reporting to the CIRB potential unanticipated problems and/or serious or continuing noncompliance**

[Add Note](#) [View Audit](#)

**Office Name**

[Add Note](#) [View Audit](#)

**Responsible Person**

[Add Note](#) [View Audit](#)

**Phone Number**

[Add Note](#) [View Audit](#)

**Email address**

Describe, in detail, how this person(s) identifies and manages and reports to the CIRB potential unanticipated problems and/or serious or continuing noncompliance. [Add Note](#) [View Audit](#)

If applicable, an attachment can be added here.

[Add Note](#) [View Audit](#)

[Add Attachment](#)

### Financial Conflicts of Interest

[Add Note](#) [View Audit](#)

10. Describe how the Signatory Institution gathers and evaluates Principal Investigator and research staff financial conflicts of interest for studies on the CIRB menu. Any policies related to the management of conflict of interest should be attached.

(Required)

If applicable, an attachment can be added here.

[Add Note](#) [View Audit](#)

[Add Attachment](#)

### Institutional Policies Pertaining to the Consent Form for CIRB-Approved Studies

[Add Note](#) [View Audit](#)

11. Describe your institutional policies and guidelines that govern the informed consent document.

(Required)

If applicable, an attachment can be added here.

[Add Note](#) [View Audit](#)

[Add Attachment](#)

12. Provide the boilerplate language that is added to the CIRB-approved consent form. This is standard language required by the institution that is inserted into the existing CIRB-approved consent form, such as, birth control language, coverage of research injury, required phone numbers for the study doctor, and a person unaffiliated with the study who can answer general clinical trial questions, etc.

[Add Note](#) [View Audit](#)

**Note:** Boilerplate language cannot replace language in the CIRB-approved consent form without CIRB approval. Any language that will be replaced must be clearly identified in the submission. Required NCI Consent Form template language and the risks for agents cannot be changed.

Please refer to the [Boilerplate Q & A](#) Quickguide for further guidance.

(Required)

If applicable, an attachment (in Word format) can be added here.

[Add Note](#) [View Audit](#)

Note: If you are submitting an updated Worksheet and have revised boilerplate language, submit a "track changes" and a clean Word version of the boilerplate language to clearly indicate what has changed from the current CIRB-approved boilerplate language.

Add Attachment

13. Provide the institutional letterhead used for the informed consent document, if applicable (attach a blank copy of letterhead to be used).

[Add Note](#) [View Audit](#)

Add Attachment

14. Provide any other institutional requirements for the informed consent documents or additional documents used in research at your institution.

[Add Note](#) [View Audit](#)

A large rectangular text area with a light blue background and a thin border. A small blue icon with the letters 'ABC' and a downward arrow is located in the top right corner of the text area.

If applicable, an attachment (in Word Format) can be added here.


[Add Note](#) [View Audit](#)

Add Attachment

15. Provide the institution's plan for implementation of changes to the boilerplate language, letterhead, or other institutional requirement identified in this submission for any study currently open with the CIRB. This language should be used for any initial study opening with the CIRB.

[Add Note](#) [View Audit](#)

(Required)

A large rectangular text area with a light blue background and a thin border. A small blue icon with the letters 'ABC' and a downward arrow is located in the top right corner of the text area.

## Community Descriptors

[Add Note](#) [View Audit](#)

16. Does the community have a positive attitude toward the conduct of research?

(Required)

- Yes  
 No

If No, please explain.

[Add Note](#) [View Audit](#)

A large rectangular text area with a light blue background and a thin border. A small blue icon with the letters 'ABC' and a downward arrow is located in the top right corner of the text area.

[Add Note](#) [View Audit](#)

**17. Is there anything else the CIRB should know about the anticipated study participant population at the Signatory Institution?**

*(Required)*

Yes  
 No

[Add Note](#) [View Audit](#)

**If Yes, please explain.**

[Add Note](#) [View Audit](#)

**If applicable, an attachment can be added here.**

[Add Attachment](#)

[Add Note](#) [View Audit](#)

**Additional Information**

**18. Is there anything else the CIRB should know about the Signatory Institution's local context?**

*(Required)*

Yes  
 No

[Add Note](#) [View Audit](#)

**If Yes, please explain.**

[Add Note](#) [View Audit](#)

**If applicable, an attachment can be added here.**

[Add Attachment](#)

[Add Note](#) [View Audit](#)

**Additional Materials for Review (If Applicable)**

**Complete this section if you have any of the following additional materials to be reviewed by the CIRB.**

**19. Translated documents.** Translated documents include, the institution's boilerplate language, short forms, template assent form, or template document for consent at age of majority. If short forms are being submitted for review, attach your institutional policy for short form use.

**Note:** The following documents are required when submitting translated material:

1. CIRB-approved English language document(s) corresponding to the translated document with a version or version date
2. Translated version(s) of the CIRB-approved English language document with a version or version date that matches the English version
3. Translator's Certificate(s) of Accuracy or equivalent document(s) with reference to the version or version date

[Add Note](#) [View Audit](#)

**If applicable, an attachment can be added here.**

[Add Attachment](#)

[Add Note](#) [View Audit](#)

**20. Assent form or consent at the age of majority form documents used by the Signatory Institution.**  
(Required)

ABC

*Enter "N/A" for adult studies or how assent is documented for Pediatric and age of majority.*

[Add Note](#) [View Audit](#)

**If applicable, an attachment can be added here**

[Add Attachment](#)

[Next](#) [Save for Later](#) [More ▾](#)

**Form Completed**

You've completed the form. You can now either save the form for later revision, or submit it.

[Go Back](#) [Save for Later](#) [Print](#) [Submit](#)